Business Description
Tevogen Bio Holdings Inc. is a clinical-stage biotech company founded in 2020 and based in Warren, New Jersey, focused on creating ready-to-use T cell treatments for infectious diseases, cancers, and other serious conditions. Its lead therapy, TVGN 489, has advanced through Phase 1 trials targeting COVID-19 and related complications, including Long COVID and immune-compromised patients with B-cell cancers. The company also has several treatments in early-stage research aimed at cervical cancer, throat cancer, multiple sclerosis, Epstein-Barr virus lymphomas, and hepatitis B.
